切换导航
  • 比较产品

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

main product photo

ImmunoCult™ 小鼠Treg分化添加物

小鼠naïve CD4+ T细胞向调节性T细胞（Tregs）细胞分化的无血清培养添加物

只有 %1 左
率先评论此产品
¥8,562.00
添加并比较

产品号 #（选择产品）

产品号 #10957_C

小鼠naïve CD4+ T细胞向调节性T细胞（Tregs）细胞分化的无血清培养添加物

产品优势

  • 为诱导从C57BL/6小鼠脾脏分选的naive CD4+T细胞向Tregs分化而优化
  • 作为100X浓缩物供应；解冻和混匀后，可直接添加到培养基中
立即询价
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

ImmunoCult™小鼠Treg分化添加物包含重组小鼠和人细胞因子的组合以及小分子，优化用于促进小鼠naïve CD4+ T细胞向调节性T细胞（Tregs）分化。该添加物与含有胎牛血清和其他补充剂的RPMI 1640培养基（产品号 #36750）以及抗小鼠CD3和抗小鼠CD28单克隆抗体作为激活剂体系搭配使用。

本产品推荐用于：

•研究小鼠naïve T细胞分化和Treg功能的调节

•开发将naïve T细胞扩增以及向Treg亚群极化的工艺流程

 

包含
• 重组小鼠白细胞介素 2 (IL-2)
• 重组人转化生长因子 β (TGF-β)
• 全反式维甲酸 (ATRA)
 
分类
添加剂
 
细胞类型
T 细胞，T 细胞，CD4+，T 细胞，调节性细胞
 
种属
小鼠
 
应用
细胞培养，分化，扩增
 
品牌
ImmunoCult
 
研究领域
免疫
 

查看更多 显示更少

实验数据

Figure 1. ImmunoCult™ Mouse Treg Differentiation Supplement Produces CD4+CD25+FOXP3+ Cells Under Treg Polarizing Conditions

Naïve CD4+ T cells were isolated from mouse splenocytes using the EasySep™ Mouse Naive CD4+ T Cell Isolation Kit (Catalog #19765), activated with plate-bound anti-CD3 and soluble anti-CD28 and cultured in medium alone (Non-polarizing cultures), or in medium supplemented with ImmunoCult™ Mouse Treg Differentiation Supplement (Polarizing cultures) for 6 days. Cells were subsequently stained with anti-CD4, anti-CD25, anti-FOXP3 and a viability dye and analyzed by flow cytometry. Shown is the expression of CD25 and FOXP3 back-gated on viable, CD4+ cells from non-polarized (A) or polarized cultures (B). The mean proportion of CD4+FOXP3+ cells is significantly higher in cells cultured in ImmunoCult™ Mouse Treg Differentiation Supplement (91 ± 2%) compared to non-polarized cells (2 ± 0.4%) (p < 0.001; n = 14). Data from experimental groups were compared using a paired T-test.

Figure 2. ImmunoCult™ Mouse Treg Differentiation Supplement Expands Viable CD4+ Cells Under Treg Polarizing Conditions

Naïve CD4+ T cells were isolated from mouse splenocytes using the EasySep™ Mouse Naive CD4+ T Cell Isolation Kit (Catalog #19765), activated with plate-bound anti-CD3 and soluble anti-CD28 and cultured in medium alone, or medium containing ImmunoCult™ Mouse Treg Differentiation Supplement for 6 days. A 3.6-fold expansion of total nuclear cells (TNC) ensues in cultures polarized with ImmunoCult Mouse Treg Differentiation Supplement (purple column), which is significantly higher compared to non-polarized cultures (grey column). (Data represent the mean ± SEM, n = 14, ***p < 0.001. Data from experimental groups were compared using a paired T-test).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
ImmunoCult™ Mouse Treg Differentiation Supplement
Catalog #
10957
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
ImmunoCult™ Mouse Treg Differentiation Supplement
Catalog #
10957
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (4)

小鼠细胞分选
产品手册
小鼠细胞分选
细胞分选相关工具
产品手册
细胞分选相关工具
Frequencies and Percentages of Mouse Immune Cell Types
挂图
Frequencies and Percentages of Mouse Immune Cell Types
Human Immune Cytokines
挂图
Human Immune Cytokines

文献 (1)

PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies Cell Reports Medicine 2024 Jul

Abstract

SummaryTumor-infiltrating regulatory T cells (TI-Tregs) elicit immunosuppressive effects in the tumor microenvironment (TME) leading to accelerated tumor growth and resistance to immunotherapies against solid tumors. Here,we demonstrate that poly-(ADP-ribose)-polymerase-11 (PARP11) is an essential regulator of immunosuppressive activities of TI-Tregs. Expression of PARP11 correlates with TI-Treg cell numbers and poor responses to immune checkpoint blockade (ICB) in human patients with cancer. Tumor-derived factors including adenosine and prostaglandin E2 induce PARP11 in TI-Tregs. Knockout of PARP11 in the cells of the TME or treatment of tumor-bearing mice with selective PARP11 inhibitor ITK7 inactivates TI-Tregs and reinvigorates anti-tumor immune responses. Accordingly,ITK7 decelerates tumor growth and significantly increases the efficacy of anti-tumor immunotherapies including ICB and adoptive transfer of chimeric antigen receptor (CAR) T cells. These results characterize PARP11 as a key driver of TI-Treg activities and a major regulator of immunosuppressive TME and argue for targeting PARP11 to augment anti-cancer immunotherapies. Graphical abstract Highlights•Tumor-derived factors upregulate PARP11 in the tumor-infiltrating Treg cells•PARP11 supports the immunosuppressive properties of Treg cells•Pharmacologic inhibition of PARP11 inactivates intratumoral Treg cells•PARP11 inhibitor augments the efficacy of immunotherapies Basavaraja et al. demonstrate that induction of PARP11 in the intratumoral regulatory T (Treg) cells is required for their regulatory functions and contributes to the immunosuppressive tumor microenvironment. The selective inhibitor of PARP11 ITK7 inactivates tumor Treg cells and improves the efficacy of immunotherapies against tumors.
View publication
View All Publications

更多信息

更多信息
物种 小鼠
Contains • Recombinant mouse interleukin 2 (IL-2) • Recombinant human transforming growth factor beta (TGF-β) • All-trans retinoic acid (ATRA)

质量声明:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.

Safety Statement:

 CA WARNING: This product can expose you to All-trans Retinoic Acid which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov

Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系